AzTrials
AzTrials

Covid19NCT04583306

The Salivary Raman COVID-19 Fingerprint

An observational study of Covid19, run by Fondazione Don Carlo Gnocchi ETS at 5 sites in Italy.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The outbreak of coronavirus disease 2019 (COVID-19), caused by infection of SARS-CoV-2, has rapidly spread to become a worldwide pandemic. Global research focused on the understanding of the biochemical infective mechanism and on the discovery of a fast, sensitive and cheap diagnostic tool, able to discriminate the… Read more about this study

Who is it for?
Ages 18 to 90 yearsHealthy volunteers can take part
Conditions the study is for
Covid19
What is being tested?
Raman analysis of saliva, characterization of the Raman database and building of the classification model
How many people
120 participants
Where
5 sitesItaly
Study dates
1 Jun 2020to 31 Dec 2022
How long will I take part?
1 Day
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Study population: The study population will be recruited from the clinics at IRCCS Fondazione Don Carlo Gnocchi: Santa Maria Nascente (Milano) and Centro Spalenza (Rovato)

Who may be able to join

  • Diagnosis of COVID-19 through nasopharyngeal swab positive for SARS-CoV-2
  • Provided written consent for the salivary analysis
  • Age between 18 and 90 years

Who cannot join

  • Oral bacterial or fungal infection in progress (e.g. oral candidiasis)
  • Age lower than 18 and higher than 90 years
  • No written consent provided

Trial locations and contacts

5 sites in 1 country.

5 sites in 1 country

Italy5 sites, 4 recruiting
  • Azienda Ospedaliera Universitaria Policlinico di Bari

    Bari, Apulia

    Paola Pierucci, MD, paola.pierucci@policlinico.ba.it

    Recruiting
  • IRCCS Fondazione Don Carlo Gnocchi, Santa Maria Nascente Hospital (Milano)

    Milan, MI, 20148

    Marzia Bedoni, PhD, 0240308874 ext. +39, mbedoni@dongnocchi.it

    LABION laboratory, 0240308533 ext. +39, labion@dongnocchi.it

    Recruiting
  • Farmaacquisition srl

    Milan, 20100

    Maria Langerame, maria.langerame@alliance-retail.it

    Recruiting
  • Università degli Studi di Milano-Bicocca

    Milan, 20100

    Active, not recruiting
  • Fondazione Don Carlo Gnocchi, Centro Spalenza

    Rovato, BS, 25038

    Luca C Bianchi, MD, 03072245414 ext. +39, lubianchi@dongnocchi.it

    Luca C Bianchi, MD

    Recruiting

Other trials in Italy

About this study

Official title: Characterization of the COVID-19 Raman Signature of Saliva as a Potential Tool for the Fast Discrimination of SARS-CoV-2 Infection and Severity

The outbreak of coronavirus disease 2019 (COVID-19), caused by infection of SARS-CoV-2, has rapidly spread to become a worldwide pandemic. Global research focused on the understanding of the biochemical infective mechanism and on the discovery of a fast, sensitive and cheap diagnostic tool, able to discriminate the current and past SARS-CoV-2 infections from a minimal invasive biofluid. The fast diagnosis of COVID-19 is fundamental in order to limit and isolate the positive cases, decreasing with a prompt intervention the infection spreading.

The aim of the project is to characterize and validate the salivary Raman fingerprint of COVID-19, understanding the principal biomolecules involved in the differences between the three experimental groups: 1) healthy subjects, 2) COVID-19 patients and 3) subjects with a past infection by COVID-19. The large amount of Raman data will be used to create a salivary Raman database, associating each data with the relative clinical data collected.

Read more

Starting from the preliminary results and protocols of the Laboratory of Nanomedicine and Clinical Biophotonics (LABION) - IRCCS Fondazione Don Gnocchi Milano, the saliva collected from each experimental group will be analysed using Raman spectroscopy. All the data will be processed for the baseline, shift and normalization in order to homogenize the signals collected and creating in this way the Raman database. The average spectrum calculated from each group will be characterized, identifying the principal families of biological molecules responsible for the spectral differences.

EXPECTED RESULTS: Verify the possibility to use Raman spectroscopy on saliva samples for the identification of subjects affected by COVID-19. The principal aim of the project is to create a classification model able to: discriminate COVID-19 current and past infection, identify the principal biological molecules altered in saliva during the infection, predict the clinical course of newly diagnosed COVID-19 patients, translation and application of the classification model to a portable Raman for the test of a point of care.

Read the detailed description

BACKGROUND/RATIONALE: The outbreak of coronavirus disease 2019 (COVID-19), caused by infection of SARS-CoV-2, has rapidly spread to become a worldwide pandemic. Global research focused on the understanding of the biochemical infective mechanism and on the discovery of a fast, sensitive and cheap diagnostic tool, able to discriminate the current and past SARS-CoV-2 infections from a minimal invasive biofluid. The fast diagnosis of COVID-19 is fundamental in order to limit and isolate the positive cases, decreasing with a prompt intervention the infection spreading. Moreover, the prediction of the respiratory infection severity could be of crucial importance for the fast identification and discrimination between mild clinical course, severe illness, and Acute Respiratory Distress Syndrome (ARDS). One of the first infection sites of SARS-CoV-2 is the oral cavity where the virus is able to bind and penetrate through the ACE2 receptors present on the epithelial cells of the salivary glands. Thus, a high concentration of virus particles could be found in saliva in the preliminary phases of the infection. Saliva is a complex biofluid composed of bioactive molecules that can be collected with a really minimal-invasive procedure. Raman spectroscopy is a non-invasive, fast and label-free vibrational technique, able to provide information regarding presence, concentration, environment, modifications and interactions of all the biochemical species present in a specific biofluid. Using the Raman spectroscopy, the investiators will analyze saliva collected from healthy subjects, patients affected by COVID-19 and subjects with a past infection by COVID-19. The data collected will be analyzed and used to create a Raman database able to provide a classification model based on machine learning. The possibility to monitor and characterize a potential salivary COVID-19 fingerprint could be of crucial importance for the monitoring and discrimination of COVID-19 subjects with a current and past infection from the healthy subjects.

OBJECTIVES: The aim of the project is to characterize and validate the salivary Raman fingerprint of COVID-19, understanding the principal biomolecules involved in the differences between the three experimental groups: 1) healthy subjects, 2) COVID-19 patients and 3) subjects with a past infection by COVID-19. The large amount of Raman data will be used to create a salivary Raman database, associating each data with the relative clinical data collected. The Raman database will be used for the creation of a classification model through the application of multivariate analysis in terms of principal component analysis and linear discriminant analysis. This classification model will provide a fast tool for the discrimination of the COVID-19 condition, potentially providing also information on the respiratory clinical course of the patient. The model will be translated for the application to a portable Raman spectrometer, leading to the creation of a Raman Point of Care METHODS: Starting from the preliminary results and protocols of the Laboratory of Nanomedicine and Clinical Biophotonics (LABION) - IRCCS Fondazione Don Gnocchi Milano, the saliva collected from each experimental group will be analysed using Raman spectroscopy. All the data will be processed for the baseline, shift and normalization in order to homogenize the signals collected and creating in this way the Raman database. The average spectrum calculated from each group will be characterized, identifying the principal families of biological molecules responsible for the spectral differences. Consecutively, all the spectra will be processed through multivariate analysis (principal component analysis and linear discriminant analysis) obtaining in this way the classification model. LOOCV will be used for the training of the classification model, which will be questioned using the subset validation analysis. The partial correlation coefficient (Pearson's and Spearman's correlation) will be used for the Raman correlation with the clinical parameter (e.g. COVID-19 clinical course) using as control covariates the age and sex of the subjects. The classification model will be then translated and used as point of care using a portable Raman equipped with a laser emitting at 785 nm, with a comparable spectral resolution.

  • SAMPLE COLLECTION: Saliva will be collected with Salivette (SARSTEDT, Germany), following the manufacturer's instructions. The cotton swab will be inserted in the subject mouth and chewed for 60 seconds. The saliva collection will be achieved through centrifugation of the swab (1000 g x 2 min), recording all the related parameters (storage temperature and the time between collection and analysis). All the collection procedures will be performed at least two hours after the last meal and teeth brushing.
  • SAMPLE PROCESSING: Before the analysis, saliva (3 ul) will be deposited on aluminum foil and dried overnight. The aluminum foil is fundamental to achieve the Surface Enhanced Raman Scattering, increasing the saliva Raman signal.
  • DATA COLLECTION: Raman spectra will be acquired using an Aramis Raman microscope (Horiba Jobin-Yvon, France) equipped with a laser light source operating at 785 nm with 100% (512mW) laser power. Acquisition time will be set at 30 seconds with double acquisition and 2 seconds delay time to prevent the formation of artifact spectra. Before each analysis, the instrument will be calibrated using the reference band of silicon. All the signals will be acquired in the region between 400 and 1600 cm-1 with a resolution of 0.8cm-1, acquiring at least 25 spectra following a square-map. The software package LabSpec 6 (Horiba Jobin-Yvon) will be used for map design and the acquisition of spectra.
  • DATA ANALYSIS: All the data will be fit using a fourth-degree polynomial curve to set the baseline and consecutively normalized using unit vector. The contribution of aluminum will be removed from each spectrum. The statistical analysis will be performed using the multivariate approach. Briefly, principal component analysis and linear discriminant analysis will be applied to extract the principal components and the canonical variables. These features will be used for the leave one out cross-validation (LOOCV), subset validation and correlation with the clinical parameters. Mann-Whitney will be performed on PCs scores to verify the differences statistically relevant between the analysed groups. The analysis will be performed using Origin software (OriginLab, USA)
  • CORRELATION: Partial correlation with Pearson's and Spearman's coefficients will be performed on the variables extracted and the clinical parameters, using as control covariates the age and sex of the subjects. Only values with p < 0.001 will be considered as statistically relevant.
  • TRANSLATION: The data and the classification model will be applied with a portable Raman equipped with a laser emitting at 785 nm and with a spectral resolution comparable with the one used for the previous analysis.
Conditions
Covid19
Being tested
Raman analysis of saliva, characterization of the Raman database and building of the classification model
Keywords
Covid-19, Raman Spectroscopy, Machine Learning, Classification Model, Diagnosis
Medical subject headings
COVID-19, Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Raman analysis of saliva, characterization of the Raman database and building of the classification modelOther

    Saliva will be collected, processed and analysed through Raman spectroscopy. Data acquired will be normalized and treated for the creation of the classification model.

Study groups in NCT04583306
Study groupRoleWhat they receive
Healthy Subjects40 Healthy Subjects in a good state of health comparable by age and sex with the other selected groups and with a negative test for SARS-CoV-2 or collected before the pandemic event
Receives: Other: Raman analysis of saliva, characterization of the Raman database and building of the classification model
COVID-19 Positive40 subjects affected by COVID-19, determined by positive nasopharyngeal test for SARS-CoV-2 and with comparable age and sex for the other selected groups
Receives: Other: Raman analysis of saliva, characterization of the Raman database and building of the classification model
COVID-19 Negative40 subjects with a past infection by SARS-CoV-2 confirmed and with at least two consecutive negative tests determined by nasopharyngeal SARS-CoV-2 assay, comparable by age and sex with the other selected groups
Receives: Other: Raman analysis of saliva, characterization of the Raman database and building of the classification model

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Identification and characterization of a new COVID-19 salivary signature through Raman spectroscopy

    The Raman analysis of saliva samples collected from patients affected by COVID-19 and with a past infection, will be used to characterize a COVID-19 signature able to discriminate subjects with a current or past infection

    Measured: One day

  2. Evaluation of the spectral differences between the experimental groups

    The Raman data collected from the experimental groups will be compared and interpolated with the huge number of Raman databases on biofluids present in literature. This procedure will provide a determination of the principal biochemical species involved in the differences between the experimental groups (e.g. viral structural protein and lipids, cytokines, inflammatory molecules, damaged biomolecules)

    Measured: One months

  3. Determination of the classification model through multivariate analysis

    The Raman database will be processed through principal component analysis and linear discriminant analysis. The consecutive leave-one out cross-validation will provide a primary discrimination model able to assign each spectra to one of the experimental group

    Measured: 6 months

  4. Correlation with the clinical data

    Raman data related to subjects with a current or past infection by SARS-CoV-2 will be correlated with the clinical data, validating in this way our methodology. The principal correlation will be carried out between the severity of the respiratory infection and the time between the first SARS-CoV-2 positive test and the last negative SARS-CoV-2 test.

    Measured: One Day

  5. Test of the methodology

    The classification model will be continuosly questioned and trained using new potential patients and adding new clinical parameters as "sub-groups" for the complete discrimination and prediction of the pathological state.

    Measured: One Year

  6. Portable Raman as point of care

    The characterized and implemented classification model will be translated to a portable Raman equipped with a laser emitting at 785 nm and with a spectral resolution comparable with the one of the bench Raman. This station will be firstly tested with patients coming to the hospital and then applied continuosly implementing the classification model with new Raman spectra and clinical data. In this way we will highly implement the accuracy, sensitivity, precision and specificity of the model.

    Measured: One Year

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Oct 2020
  2. Study start1 Jun 2020
  3. Primary completion30 Oct 2022 (estimated)
  4. Study completion31 Dec 2022 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Case-control
Time perspective
Prospective
Enrolment
120 participants (estimated)
Target duration
1 Day
IDs, dates and publications
ClinicalTrials.gov ID
NCT04583306
Sponsor's protocol ID
FDG_SalivaCOVID01
Status last verified
Feb 2022
First submitted
9 Oct 2020
Last updated
11 May 2022
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Publications

  • Feng Z, Yu Q, Yao S, Luo L, Zhou W, Mao X, Li J, Duan J, Yan Z, Yang M, Tan H, Ma M, Li T, Yi D, Mi Z, Zhao H, Jiang Y, He Z, Li H, Nie W, Liu Y, Zhao J, Luo M, Liu X, Rong P, Wang W. Early prediction of disease progression in COVID-19 pneumonia patients with chest CT and clinical characteristics. Nat Commun. 2020 Oct 2;11(1):4968. doi: 10.1038/s41467-020-18786-x.

    PubMed 33009413
  • Carlomagno C, Cabinio M, Picciolini S, Gualerzi A, Baglio F, Bedoni M. SERS-based biosensor for Alzheimer disease evaluation through the fast analysis of human serum. J Biophotonics. 2020 Mar;13(3):e201960033. doi: 10.1002/jbio.201960033. Epub 2020 Jan 1.

    PubMed 31868266
  • Carlomagno C, Banfi PI, Gualerzi A, Picciolini S, Volpato E, Meloni M, Lax A, Colombo E, Ticozzi N, Verde F, Silani V, Bedoni M. Human salivary Raman fingerprint as biomarker for the diagnosis of Amyotrophic Lateral Sclerosis. Sci Rep. 2020 Jun 23;10(1):10175. doi: 10.1038/s41598-020-67138-8.

    PubMed 32576912
  • Gualerzi A, Niada S, Giannasi C, Picciolini S, Morasso C, Vanna R, Rossella V, Masserini M, Bedoni M, Ciceri F, Bernardo ME, Brini AT, Gramatica F. Raman spectroscopy uncovers biochemical tissue-related features of extracellular vesicles from mesenchymal stromal cells. Sci Rep. 2017 Aug 29;7(1):9820. doi: 10.1038/s41598-017-10448-1.

    PubMed 28852131

Questions about this trial

What is this clinical trial studying?

An observational study of Covid19, run by Fondazione Don Carlo Gnocchi ETS at 5 sites in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 11 May 2022. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 5 sites in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Marzia Bedoni, PhD (0240308874 ext. +39, mbedoni@dongnocchi.it), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Identification and characterization of a new COVID-19 salivary signature through Raman spectroscopy (time frame: One day). The study lists 6 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT04583306, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 11 May 2022.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in